Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial

Gut

Volumn 67, Issue 7, 2018, Pages 1239-1246

  Mera, Robertino M ^a   Bravo, Luis E ^b   Constanza Camargo, M ^c   Bravo, Juan C ^b   Delgado, Alberto G ^a   Romero Gallo, Judith ^a   Yepez, Maria C ^d   Realpe, José L ^d   Schneider, Barbara G ^a   Morgan, Douglas R ^a   Peek, Richard M ^a,e   Correa, Pelayo ^a   Wilson, Keith T ^a,e,f   Blanca Piazuelo, M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSIDAD DEL VALLE   (Colombia)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSIDAD DE NARIÑO   (Colombia)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH ATROPHY; STOMACH BIOPSY; STOMACH CANCER; STOMACH LESION; COMPLICATION; DISEASE EXACERBATION; DRUG ADMINISTRATION; HELICOBACTER PYLORI; METAPLASIA; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PRECANCER; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STOMACH TUMOR;

ANTIINFECTIVE AGENT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METAPLASIA; MIDDLE AGED; PRECANCEROUS CONDITIONS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 85026310634     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-311685     Document Type: Article

References (40)

1. Iarc working group on the evaluation of carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:177-240.
2. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-first american cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 1992;52:6735-40.
3. Correa P, Haenszel W, Cuello C, et al. a model for gastric cancer epidemiology. Lancet 1975;2:58-60.
4. Correa P, Haenszel W, Cuello C, et al. gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990;50:4737-40.
5. De Vries AC, van grieken NC, looman CW, et al. gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the netherlands. Gastroenterology 2008;134:945-52.
6. Song H, Ekheden Ig, Zheng Z, et al. incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ 2015;351:h3867.
7. Tan VP, Wong Bc. gastric cancer chemoprevention: the current evidence. Gastroenterol Clin North Am 2013;42:299-316.
8. Leung WK, Lin Sr, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-9.
9. You WC, Brown LM, Zhang L, et al. randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-83.
10. Ma Jl, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012;104:488-92.
11. Li WQ, Ma JL, Zhang L, et al. effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst 2014;106:dju116.
12. Wong Bc, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of china: a randomized controlled trial. JAMA 2004;291:187-94.
13. Lee YC, Chiang TH, Chou CK, et al. association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016;150:1113-24.
14. Correa P, Fontham ET, Bravo JC, et al. chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
15. Mera R, Fontham ET, Bravo LE, et al. long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536-40.
16. Garvey W, Fathi A Bigelow F. Modified Steiner for the demonstration of spirochetes. J Histotechnol 1985;8:15-7.
17. Jass Jr, Filipe Mi. the mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J 1981;13:931-9.
18. Matsukura N, Suzuki K, Kawachi T, et al. Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. J Natl Cancer Inst 1980;65:231-40.
19. Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol 2010;105:493-8.
20. Lauwers GY, Franceschi S, Carneiro F, et al. gastric carcinoma. in: Bosman Ft, carneiro F, Hruban rH, eds. WHO classification of tumours of the digestive system. 4th ed. lyon: international agency for research on cancer (iarc), 2010:48-58.
21. Dixon MF, Genta RM, Yardley JH, et al. classification and grading of gastritis. the updated Sydney system. international Workshop on the Histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
22. Rugge M, Correa P, Dixon MF, et al. gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000;24:167-76.
23. Kodaman N, Pazos A, Schneider BG, et al. Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proc Natl Acad Sci U S A 2014;111:1455-60.
24. Capelle LG, De Vries AC, Haringsma J, et al. the staging of gastritis with the Olga system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71:1150-8.
25. Rugge M, Correa P, Di Mario F, et al. Olga staging for gastritis: a tutorial. Dig Liver Dis 2008;40:650-8.
26. Chey WD, Wong BC. Practice Parameters committee of the american college of gastroenterology. american college of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
27. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017;66:6-30.
28. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353-67.
29. Cai X, Carlson J, Stoicov C, et al. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in c57Bl/6 mice. Gastroenterology 2005;128:1937-52.
30. Lee CW, Rickman B, Rogers AB, et al. Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic inS-gaS mice. Cancer Res 2008;68:3540-8.
31. Freedberg DE, Abrams JA, Wang TC. Prevention of gastric cancer with antibiotics: can it be done without eradicating Helicobacter pylori? J Natl Cancer Inst 2014;106:dju148.
32. Lee Yc, Chen TH, Chiu HM, et al. the benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013;62:676-82.
33. Correa P, Cuello C, Duque E. carcinoma and intestinal metaplasia of the stomach in colombian migrants. J Natl Cancer Inst 1970;44:297-306.
34. Den Hoed CM, Van Eijck BC, Capelle LG, et al. the prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer. Eur J Cancer 2011;47:1211-8.
35. Rugge M, de Boni M, Pennelli G, et al. gastritis Olga-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010;31:1104-11.
36. Rugge M, Meggio A, Pennelli G, et al. gastritis staging in clinical practice: the Olga staging system. Gut 2007;56:631-6.
37. Filipe Mi, Muñoz N, Matko I, et al. intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994;57:324-9.
38. González CA, Sanz-Anquela JM, Companioni O, et al. incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. J Gastroenterol Hepatol 2016;31:953-8.
39. González CA, Sanz-anquela JM, Gisbert JP, et al. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. a review of the evidence. Int J Cancer 2013;133:1023-32.
40. Rugge M, Fassan M, Pizzi M, et al. Operative link for gastritis assessment gastritis staging incorporates intestinal metaplasia subtyping. Hum Pathol 2011;42:1539-44.